Denmark · Delayed Price · Currency is DKK Aktieselskabet Schouw & Co. Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered EBITDA and EBT growth despite a 3% revenue decline, with strong operational execution and deleveraging. Segment performance was mixed, but guidance for the full year is maintained, and the BioMar IPO process has advanced.
Fiscal Year 2025
-
Revenue and EBITDA declined slightly due to raw material and Forex headwinds, but cash flow hit a record high and leverage improved. Most segments delivered EBITDA growth, with strong guidance for 2026 and continued focus on capital discipline and efficiency.
-
Q3 saw a 4% revenue decline but a 5% EBITDA increase, driven by strong cost control and margin management. BioMar delivered record EBITDA despite biological headwinds, while other segments showed mixed results amid ongoing market uncertainties.
-
Revenue and EBITDA declined slightly year-over-year amid ongoing market volatility, but strong cash flow and reduced debt supported continued investment. BioMar, GPV, and HydraSpecma showed operational improvements, while Borg Automotive faced margin pressure and restructuring.
-
Q1 saw flat revenue and a 13% EBITDA decline, with strong cash flow and positive one-offs. Segment results were mixed, but full-year guidance is maintained, and BioMar's IPO evaluation is advancing. Market volatility and tariff risks persist.
Fiscal Year 2024
-
Revenue declined 7% to DKK 34.7 billion in 2024, but EBITDA hit a record DKK 2.93 billion, with strong cash flow and reduced leverage. Segment results were mixed, with BioMar and BORG Automotive showing profit growth, while GPV and Fibertex Personal Care faced headwinds. 2025 guidance is cautiously optimistic.
-
Revenue and EBITDA declined year-over-year amid soft demand, inflation, and intense competition, but margins were largely maintained through cost reductions and efficiency gains. BioMar's strong performance and a potential IPO were key highlights, while guidance was narrowed across segments.
-
Q2 2024 saw a 5% revenue decline but an 11% EBITDA increase, driven by BioMar's strong margin uplift. Guidance for 2024 EBITDA was raised, despite softening demand and challenges in industrial segments, with profit protection and efficiency measures in place.